210 related articles for article (PubMed ID: 33741260)
1. Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Bryson E; Sakach E; Patel U; Watson M; Hall K; Draper A; Davis C; Goyal S; Alese O; Akce M; Shaib W; El-Rayes B; Szabo S; Wu C
Clin Colorectal Cancer; 2021 Jun; 20(2):153-160. PubMed ID: 33741260
[TBL] [Abstract][Full Text] [Related]
2. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
3. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Hennessy BT; Gauthier AM; Michaud LB; Hortobagyi G; Valero V
Ann Oncol; 2005 Aug; 16(8):1289-96. PubMed ID: 15890665
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
6. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH
Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686
[TBL] [Abstract][Full Text] [Related]
7. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Lubner SJ; Loconte NK; Holen KD; Schelman W; Thomas JP; Jumonville A; Eickhoff JC; Seo S; Mulkerin DL
Clin Colorectal Cancer; 2010 Jul; 9(3):157-61. PubMed ID: 20643620
[TBL] [Abstract][Full Text] [Related]
9. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Borner MM; Dietrich D; Stupp R; Morant R; Honegger H; Wernli M; Herrmann R; Pestalozzi BC; Saletti P; Hanselmann S; Müller S; Brauchli P; Castiglione-Gertsch M; Goldhirsch A; Roth AD
J Clin Oncol; 2002 Apr; 20(7):1759-66. PubMed ID: 11919232
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
[TBL] [Abstract][Full Text] [Related]
15. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Giessen C; Moosmann N; Heinemann V
Br J Cancer; 2011 Jul; 105(2):206-11. PubMed ID: 21750558
[TBL] [Abstract][Full Text] [Related]
16. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Garcia-Alfonso P; Muñoz-Martin A; Mendez-Ureña M; Quiben-Pereira R; Gonzalez-Flores E; Perez-Manga G
Br J Cancer; 2009 Oct; 101(7):1039-43. PubMed ID: 19738605
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Wong NS; Fernando NH; Bendell JC; Morse MA; Blobe GC; Honeycutt W; Pang H; Hurwitz HI
Clin Colorectal Cancer; 2011 Sep; 10(3):210-6. PubMed ID: 21855046
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Skof E; Rebersek M; Hlebanja Z; Ocvirk J
BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
